Novel targeted anti-tumor nanoparticles developed from folic acid-modified 2-deoxyglucose

19Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

The glucose analog, 2-deoxyglucose (2-DG), specifically inhibits glycolysis of cancer cells and interferes with the growth of cancer cells. However, the excellent water solubility of 2-DG makes it difficult to be concentrated in tumor cells. In this study, a targeted nano-pharmacosome was developed with folic acid-modified 2-DG (FA-2-DG) by using amino ethanol as a cleavable linker. FA-2-DG was able to self-assemble, forming nano-particles with diameters of 10–30 nm. The biological effects were evaluated with cell viability assays and flow cytometry analysis. Compared with a physical mixture of folic acid and 2-DG, FA-2-DG clearly reduced cell viability and resulted in cell cycle arrest. A computational study involving docking simulation suggested that FA-2-DG can dock into the same receptor as folic acid, thus confirming that the structural modification did not affect the targeting performance. The results indicated that the nano-pharmacosome consisting of FA-2-DG can be used for targeting in a nano-drug delivery system.

Cite

CITATION STYLE

APA

Jin, S., Du, Z., Guo, H., Zhang, H., Ren, F., & Wang, P. (2019). Novel targeted anti-tumor nanoparticles developed from folic acid-modified 2-deoxyglucose. International Journal of Molecular Sciences, 20(3). https://doi.org/10.3390/ijms20030697

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free